These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21420339)

  • 1. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy.
    Filippon L; Vanzin CS; Biancini GB; Pereira IN; Manfredini V; Sitta A; Peralba Mdo C; Schwartz IV; Giugliani R; Vargas CR
    Mol Genet Metab; 2011 Jun; 103(2):121-7. PubMed ID: 21420339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy.
    Filippon L; Wayhs CA; Atik DM; Manfredini V; Herber S; Carvalho CG; Schwartz IV; Giugliani R; Vargas CR
    Mutat Res; 2011 Apr; 721(2):206-10. PubMed ID: 21334454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation.
    Jacques CE; Donida B; Mescka CP; Rodrigues DG; Marchetti DP; Bitencourt FH; Burin MG; de Souza CF; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2016 Sep; 1862(9):1608-16. PubMed ID: 27251652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy.
    Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR
    Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy.
    Donida B; Marchetti DP; Biancini GB; Deon M; Manini PR; da Rosa HT; Moura DJ; Saffi J; Bender F; Burin MG; Coitinho AS; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2015 May; 1852(5):1012-9. PubMed ID: 25701642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
    Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
    Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy.
    Jurecka A; Krumina Z; Żuber Z; Różdżyńska-Świątkowska A; Kłoska A; Czartoryska B; Tylki-Szymańska A
    Am J Med Genet A; 2012 Feb; 158A(2):450-4. PubMed ID: 22246721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of oxidative stress and mitochondrial function in a type II mucopolysaccharidosis cellular model: in vitro effects of genistein and coenzyme Q10.
    Jacques CED; Lopes FF; Poletto E; Vera LNP; Vianna P; Reinhardt LS; Baldo G; Vargas CR
    Metab Brain Dis; 2023 Feb; 38(2):519-529. PubMed ID: 36029429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients.
    Likidlilid A; Patchanans N; Peerapatdit T; Sriratanasathavorn C
    J Med Assoc Thai; 2010 Jun; 93(6):682-93. PubMed ID: 20572373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hunter disease before and during enzyme replacement therapy.
    Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E
    Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature.
    Jurecka A; Żuberuber Z; Opoka-Winiarska V; Węgrzyn G; Tylki-Szymańska A
    Mol Genet Metab; 2012 Nov; 107(3):508-12. PubMed ID: 22926198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of genistein and coenzyme Q10 in oxidative damage and mitochondrial membrane potential in an attenuated type II mucopolysaccharidosis cellular model.
    Delgado CA; Poletto E; Vera LNP; Jacques CED; Vianna P; Reinhardt LS; Baldo G; Vargas CR
    Cell Biochem Funct; 2024 Mar; 42(2):e3932. PubMed ID: 38332678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
    Burton BK; Whiteman DA;
    Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.